Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Rating of "Buy" from Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have received a consensus recommendation of "Buy" from the nine brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $211.13.

KRYS has been the topic of a number of recent analyst reports. Citigroup dropped their price target on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a research report on Friday, May 16th. Chardan Capital reiterated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research note on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a report on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Guggenheim lowered their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds have recently modified their holdings of the stock. Strs Ohio acquired a new position in shares of Krystal Biotech in the 1st quarter valued at $1,244,000. Intech Investment Management LLC lifted its stake in Krystal Biotech by 11.4% during the first quarter. Intech Investment Management LLC now owns 12,078 shares of the company's stock valued at $2,178,000 after buying an additional 1,239 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock valued at $103,764,000 after buying an additional 365,304 shares in the last quarter. Woodline Partners LP lifted its position in shares of Krystal Biotech by 0.4% in the 1st quarter. Woodline Partners LP now owns 222,043 shares of the company's stock valued at $40,034,000 after acquiring an additional 941 shares in the last quarter. Finally, S Squared Technology LLC boosted its stake in Krystal Biotech by 2.1% in the 1st quarter. S Squared Technology LLC now owns 97,215 shares of the company's stock worth $17,528,000 after purchasing an additional 2,000 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

Shares of KRYS traded up $1.12 during mid-day trading on Friday, reaching $132.03. 234,692 shares of the company's stock traded hands, compared to its average volume of 311,039. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $219.34. The business's 50-day moving average price is $151.55 and its 200-day moving average price is $163.81. The stock has a market capitalization of $3.82 billion, a P/E ratio of 44.16 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The company had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Equities research analysts anticipate that Krystal Biotech will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).